# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!



Warts, hypogammaglobulinemia, infections, and myelokathexis
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 10 results.
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Status: Recruiting
Last Changed: Jun 16, 2020
First Received: Jun 21, 2019
Disease(s): WHIM Syndrome
Intervention(s): Mavorixafor, Placebo
Locations: University of California San Diego Health/Rady Children's Hospital, San Diego, California, United States
California Dermatology Institute, Thousand Oaks, California, United States
Johns Hopkins University Medical Center, Baltimore, Maryland, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Aarhus University Hospital, Aarhus, Denmark
... and 3 other locations.
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
Status: Recruiting
Last Changed: Jun 29, 2020
First Received: Aug 28, 2009
Disease(s): Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
Intervention(s): Mozobil (TM)
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
Status: Recruiting
Last Changed: Dec 27, 2019
First Received: Feb 19, 2018
Disease(s): Multiple Myeloma, Lymphoma
Intervention(s): 68Ga-Pentixafor
Locations: Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science, Beijing, China
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Status: Recruiting
Last Changed: Jun 24, 2020
First Received: Feb 18, 2020
Disease(s): Waldenstrom Macroglobulinemia
Intervention(s): Mavorixafor, Ibrutinib
Locations: Colorado Blood Cancer Institute, Denver, Colorado, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mass General Hospital Cancer Center, Boston, Massachusetts, United States
MD Anderson Cancer Center, Houston, Texas, United States
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Status: Recruiting
Last Changed: Jan 14, 2020
First Received: Nov 16, 2015
Disease(s): Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Intervention(s): Busulfan, Cyclophosphamide, CXCR4 Antagonist, Hematopoietic Stem Cell Transplantation
Locations: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Status: Recruiting
Last Changed: Apr 10, 2020
First Received: Nov 08, 2017
Disease(s): Neuroendocrine Tumors
Intervention(s): [68Ga]Pentixafor
Locations: Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
Status: Recruiting
Last Changed: Mar 27, 2019
First Received: Mar 27, 2019
Disease(s): RCC, Metastatic Renal Cell Carcinoma
Intervention(s): Immunological and tumour characterization
Locations: IRCCS Istituto Nazionale Tumori di Napoli, Naples, Italy
Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia
Status: Not yet recruiting
Last Changed: Feb 12, 2020
First Received: Feb 10, 2020
Disease(s): Waldenstrom Macroglobulinemia
Intervention(s): Carfilzomib + Ibrutinib, Ibrutinib
Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Status: Recruiting
Last Changed: May 10, 2019
First Received: May 06, 2016
Disease(s): Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)
Intervention(s): USL311, USL311, USL311, Lomustine
Locations: Washington University, Saint Louis, Missouri, United States
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
UT Health San Antonio Cancer Center, San Antonio, Texas, United States
... and 3 other locations.
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Status: Not yet recruiting
Last Changed: Jun 11, 2020
First Received: Nov 26, 2019
Disease(s): Metastatic Pancreatic Cancer
Intervention(s): Cemiplimab, Plerixafor
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States